Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Donanemab (Kisunla; Eli Lilly and Co.) for Alzheimer Disease

Donanemab (Kisunla; Eli Lilly and Co.) is an intravenously administered amyloid beta-directed antibody indicated for the treatment of Alzheimer disease. Treatment with donanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease.